These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 11463597

  • 1. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer.
    Nielsen KG, Bisgaard H.
    Am J Respir Crit Care Med; 2001 Jul 15; 164(2):256-9. PubMed ID: 11463597
    [Abstract] [Full Text] [Related]

  • 2. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J, Ankerst J.
    Respir Med; 2008 Mar 15; 102(3):449-56. PubMed ID: 18023335
    [Abstract] [Full Text] [Related]

  • 3. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A.
    Br J Clin Pharmacol; 2004 Oct 15; 58(4):359-66. PubMed ID: 15373928
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
    Clin Ther; 2004 Oct 15; 26(10):1587-98. PubMed ID: 15598475
    [Abstract] [Full Text] [Related]

  • 5. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
    Chuchalin AG, Manjra AI, Rozinova NN, Skopková O, Cioppa GD, Till D, Kaiser G, Fashola T, Kottakis J.
    J Aerosol Med; 2005 Oct 15; 18(1):63-73. PubMed ID: 15741775
    [Abstract] [Full Text] [Related]

  • 6. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.
    Respiration; 2004 Oct 15; 71(2):126-33. PubMed ID: 15031566
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L, Rosenborg J, Bengtsson T, Lötvall J.
    Ther Adv Respir Dis; 2013 Oct 15; 7(5):264-71. PubMed ID: 23907810
    [Abstract] [Full Text] [Related]

  • 8. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ, Senn S, Mezzanotte WS.
    Contemp Clin Trials; 2008 Mar 15; 29(2):114-24. PubMed ID: 17625985
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G.
    Respiration; 2005 Mar 15; 72 Suppl 1():6-12. PubMed ID: 15915007
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Mar 15; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 11. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
    Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, Nolte H, Teper AA.
    Pediatr Pulmonol; 2014 May 15; 49(5):441-50. PubMed ID: 24019197
    [Abstract] [Full Text] [Related]

  • 12. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.
    Wallin A, Sandström T, Rosenhall L, Melander B.
    Thorax; 1993 Jun 15; 48(6):611-4. PubMed ID: 8346490
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Jun 15; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 14. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
    Brusasco V, Canonica GW, Dal Negro R, Scano G, Paggiaro P, Fabbri LM, Barisione G, D'Amato G, Varoli G, Baroffio M, Milanese M, Mereu C, Crimi E.
    J Aerosol Med Pulm Drug Deliv; 2011 Oct 15; 24(5):235-43. PubMed ID: 21689019
    [Abstract] [Full Text] [Related]

  • 15. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J.
    Eur Respir J; 1997 Nov 15; 10(11):2484-9. PubMed ID: 9426083
    [Abstract] [Full Text] [Related]

  • 16. The duration of action of inhaled formoterol dry powder.
    Quebe-Fehling E, Brambilla R, Bromly CL, Fishwick K, Walters EH, Hendrick DJ.
    Br J Clin Pract; 1996 Dec 15; 50(8):446-9. PubMed ID: 9039716
    [Abstract] [Full Text] [Related]

  • 17. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.
    Cazzola M, Centanni S, Regorda C, di Marco F, di Perna F, Carlucci P, Boveri B, Santus P.
    Pulm Pharmacol Ther; 2001 Dec 15; 14(1):41-5. PubMed ID: 11162418
    [Abstract] [Full Text] [Related]

  • 18. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children.
    Bisgaard H, Nielsen KG.
    Am J Respir Crit Care Med; 2000 Jul 15; 162(1):187-90. PubMed ID: 10903240
    [Abstract] [Full Text] [Related]

  • 19. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
    Kaiser H, Parasuraman B, Boggs R, Miller CJ, Leidy NK, O'Dowd L.
    Ann Allergy Asthma Immunol; 2008 Sep 15; 101(3):295-303. PubMed ID: 18814453
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U.
    J Asthma; 2005 Mar 15; 42(2):101-6. PubMed ID: 15871441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.